NCT03932032

Brief Summary

This two-site study is a test of Attention Bias Modification Treatment (ABMT) among 260 youths ages 10 to 14 years with social anxiety disorder. One-half of participants will receive 8 sessions of computer administered ABMT and the other half of participants will receive 8 sessions of computer administered Neutral Control Task (NCT). The investigators hypothesize that a biomarker of attention to social threat measured using electroencephalography (EEG) and ratings of social anxiety severity will be lower in participants who receive ABMT compared to participants who receive NCT.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
206

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 26, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 30, 2019

Completed
2 months until next milestone

Study Start

First participant enrolled

July 1, 2019

Completed
6.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 15, 2026

Completed
3 months until next milestone

Results Posted

Study results publicly available

April 29, 2026

Completed
Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

6.5 years

First QC Date

April 26, 2019

Results QC Date

March 12, 2026

Last Update Submit

April 8, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • P1 Amplitude Elicited in the Dot-probe Task

    Posttreatment event related potential amplitude elicited during the emotional faces dot probe task. The investigators focused specifically on the P1 amplitude time-locked to the onset of emotional facial stimuli in the dot probe task. P1 amplitude was measured using EEG methodology. Higher scores indicate greater allocation of neural resources when viewing stimuli in the dot probe task, which can be interpreted as an indicator of greater attention orientation to emotional facial stimuli.

    post-intervention (within one week of completing the final treatment session)

  • P1 Amplitude Elicited in the Dot-probe Task

    Follow-up P1 event related potential amplitude elicited during the emotional faces dot probe task. The investigators focused specifically on the P1 amplitude time-locked to the onset of emotional facial stimuli in the dot probe task. P1 amplitude was measured using EEG methodology. Higher scores indicate greater allocation of neural resources when viewing stimuli in the dot probe task, which can be interpreted as an indicator of greater attention orientation to emotional facial stimuli.

    Follow-up (six months after completing the final treatment session)

Secondary Outcomes (6)

  • Liebowitz Social Anxiety Scale for Children and Adolescents

    post-intervention (within one week of completing the final treatment session)

  • Liebowitz Social Anxiety Scale for Children and Adolescents

    Follow-up (six months after completing the final treatment session)

  • Screen for Child Anxiety Related Emotional Disorders - Parent Version at Posttreatment

    post-intervention (within one week of completing the final treatment session)

  • Screen for Child Anxiety Related Emotional Disorders - Parent Version at Follow up

    Follow-up (six months after completing the final treatment session)

  • Screen for Child Anxiety Related Emotional Disorders - Child Version at Posttreatment

    post-intervention (within one week of completing the final treatment session)

  • +1 more secondary outcomes

Other Outcomes (4)

  • State Anxiety Before a Speech Task

    post-intervention (within one week of completing the final treatment session)

  • State Anxiety Before a Speech Task

    Follow-up (six months after completing the final treatment session)

  • State Anxiety After a Speech Task

    post-intervention (within one week of completing the final treatment session)

  • +1 more other outcomes

Study Arms (2)

Attention Bias Modification Treatment

EXPERIMENTAL

Attention Bias Modification Treatment is a computer-based attention training program.

Behavioral: Attention Bias Modification Treatment

Neutral Control Task

SHAM COMPARATOR

Neutral Control Task uses the same computer-based format as Attention Bias Modification Treatment, but includes only neutral stimuli and does not train attention.

Behavioral: Neutral Control Task

Interventions

At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.

Attention Bias Modification Treatment

At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.

Neutral Control Task

Eligibility Criteria

Age10 Years - 14 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Be between ages 10 and 14 years
  • meet DSM5 criteria for a diagnosis of Social Anxiety Disorder
  • presence of any coexisting psychiatric diagnoses must be of lesser severity than Social Anxiety Disorder
  • have no current psychotropic medication other than a stable dose of stimulant or non-stimulant medication for coexisting ADHD

You may not qualify if:

  • meet DSM5 criteria for Autism Spectrum Disorder, Intellectual Disability, Bipolar Disorder, Tourette's Disorder, Psychotic Disorders, or Substance Use Disorders
  • show high likelihood of hurting self or others
  • be a victim of undisclosed abuse requiring investigation/ supervision by the Department of Social Services
  • have an uncorrected vision or physical disability that interferes with the ability to click a mouse button rapidly and repeatedly
  • have a history of neurological illness, including seizures/epilepsy, or head injury with loss of consciousness \> 5 minutes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Yale Child Study Center Program for Anxiety and Mood Disorders

New Haven, Connecticut, 06520, United States

Location

Florida International University Center for Children and Families

Miami, Florida, 33199, United States

Location

Results Point of Contact

Title
Jeremy Pettit
Organization
Florida International University

Study Officials

  • Jeremy W Pettit, PhD

    Florida International University

    PRINCIPAL INVESTIGATOR
  • Wendy K Silverman, PhD

    Yale University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 26, 2019

First Posted

April 30, 2019

Study Start

July 1, 2019

Primary Completion

January 15, 2026

Study Completion

January 15, 2026

Last Updated

April 29, 2026

Results First Posted

April 29, 2026

Record last verified: 2026-04

Locations